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Edited by Stuart FergusonAbstract Caspase-14, a cysteine protease with restricted tissue
distribution, is highly expressed in diﬀerentiated epidermal
keratinocytes. Here, we extracted soluble proteins from stratum
corneum (SC) of human epidermis and demonstrate that the
extract cleaves tetrapeptide caspase substrates. The activity
decreased to below 10% when caspase-14 was removed by
immunodepletion showing that caspase-14 is the predominant
caspase in SC. In contrast to normal SC, where caspase-14 was
present exclusively in its processed form, incompletely matured
SC of parakeratotic skin from psoriasis and seborrheic derma-
titis contained both procaspase-14 and caspase-14 subunits.
Fractionation of extract from parakeratotic SC revealed that the
peak caspase activity coeluted with processed caspase-14 but not
with procaspase-14. Our results suggest that during regular
terminal keratinocyte diﬀerentiation, endogenous procaspase-14
is converted to caspase-14 subunits that are catalytically active
in the outermost layers of normal human skin.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Caspases are cysteine proteases that cleave target proteins at
speciﬁc aspartate residues. They are expressed as proenzymes
that are activated by dimerization and proteolytic processing
to a tetrameric complex consisting of two large and two small
subunits. 11 human caspases have been described, i.e., casp-
ases-1 to 10 and caspase-14 (for review see [1]). Caspase-11 and
caspase-13 represent the murine and the bovine homologs of
human caspase-4 [2,3] and caspase-12 is non-functional in
humans because of deleterious mutations in its open reading
frame [4,5]. Caspases-2, 3, 6, 7, 8, 9, and 10 have been found to
act pro-apoptotically by either transducing a cell death signal
in the proteolytic caspase cascade or by cleaving various cel-
lular proteins that are required for survival. By contrast,* Corresponding author. Fax: +43-1-4034922.
E-mail address: leopold.eckhart@meduniwien.ac.at (L. Eckhart).
Abbreviations: SC, stratum corneum; SCE, stratum corneum extract;
pI, isoelectric point; mOD405, milli-units of optical density at 405 nm
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doi:10.1016/j.febslet.2004.10.046caspases-1, 4, and 5 are implicated in the processing of
proforms of interleukin-1b and interleukin-18, two pro-
inﬂammatory cytokines [1].
Caspase-14, the caspase family member identiﬁed most re-
cently [6–8], is unique in its restricted tissue expression pat-
tern. It is expressed in diﬀerentiated keratinocytes of the
epidermis, in hair follicles and in sebaceous glands [9–13], but
only at few sites outside the skin, i.e., the Hassall’s corpus-
cules of the thymus, the choroid plexus of the brain and the
pigmented layer of the retina. Expression of caspase-14 is
suppressed in human epidermal keratinocytes when terminal
diﬀerentiation is blocked by the pharmaceutical agent all-
trans retinoic acid [14]. Although it shares structural features
with other caspases, caspase-14 is not activated in classical
apoptosis after death receptor stimulation or DNA damage
[11]. In contrast, caspase-14 is processed into its subunits
during the terminal diﬀerentiation of keratinocytes in vitro
and in vivo [9,15].
A physiological protein substrate of caspase-14 has not
been identiﬁed so far and controversial data on activity of
caspase-14 have been reported. Whereas recombinant cas-
pase-14 produced in bacteria has been found to process the
tetrapeptide substrate DEVD [7], other studies could not
detect aspartase activity [8]. Recently, Mikolajczyk and col-
leagues reported that peptidolytic activity of recombinant
caspase-14 can be induced by granzyme B cleavage and in-
cubation in the presence of kosmotropic salts such as sodium
citrate that had previously been found to dimerize re-
combinant prodomain-less procaspases-8 and -9 [16,17]. In
the present study, we extracted endogenous caspase-14 from
stratum corneum (SC) of human epidermis and show for the
ﬁrst time that it is capable of cleaving tetrapeptide caspase
substrates.2. Materials and methods
2.1. Antibodies
A polyclonal rabbit antibody was raised against recombinant His-
tagged human procaspase-14 according to standard protocols. The
antibody does not cross-react with other caspases as evidenced by the
absence of bands: (i) on Western blots of total protein preparations
from HeLa cells, which express caspases-1 to 10 and (ii) on protein
preparations from non-diﬀerentiated keratinocytes, which express all
human caspases except caspase-5 and caspase-14 (not shown). Preab-ation of European Biochemical Societies.
Fig. 1. SC of normal skin contains only the subunits of caspase-14,
whereas parakeratotic SC also contains unprocessed procaspase-14.
Stratum corneum (SC) squames from the heels of a healthy individual
(A), from psoriatic plaques (B), and from a patient with seborrheic
dermatitis (C) were immunostained for caspase-14 (red). Nuclear
counterstaining was done with hematoxylin (blue). Absence of nuclei
established normal diﬀerentiation (orthokeratosis) in plantar SC (A),
whereas retention of nuclei indicated incomplete cell diﬀerentiation
(parakeratosis) (B,C). Original magniﬁcations, 1000. Caspase-14
protein species were determined by Western blot analysis of SC
squames extracted with PBS (D, left panel) or SDS-buﬀer (D, right
panel). Bands corresponding to procaspase-14 as well as caspase-14
subunits p17 and p11 are indicated by arrows on the right. Lanes 1 and
4, normal SC; lanes 2 and 5, psoriatic SC; lanes 3 and 6, seborrheic
dermatitis SC.
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Western blot analysis of skin proteins prevents the appearance of
bands at the size predicted for caspase-14 [18]. This conﬁrms that the
tissue-derived proteins that are recognized by the antibody are caspase-
14 protein species. In some experiments, a polyclonal anti-mouse
caspase-14 antibody that cross-reacts with human caspase-14 was used
for Western blotting [9,11]. A monoclonal mouse anti-human caspase-
14 antibody was purchased from Upstate, Lake Placid, NY. An anti-
caspase-1 antibody from Biomol (Plymouth, PA) was used for Western
blot analysis.
2.2. SC samples and protein extraction
SC was scraped oﬀ from the heels of healthy volunteers ðn ¼ 3Þ with
a scalpel blade. SC scale material was collected from diﬀerent psoriasis
patients ðn ¼ 6Þ and from a patient with seborrheic dermatitis ðn ¼ 1Þ
after obtaining their informed consent. Soluble proteins were extracted
with phosphate-buﬀered saline (PBS). 10 mg SC was incubated with
300 ll buﬀer on a rotary mixer at 4 C for 1 h. After vortexing, in-
soluble components were removed by centrifugation in a table cen-
trifuge at 15 000 rpm for 10 min. The ﬁnal concentration of total
proteins was approximately 0.8 mg/ml. Alternatively, proteins were
extracted by incubation in a buﬀer containing 1% SDS and 50 mM
Tris, pH 7.5, at 95 C for 10 min.
2.3. Anion exchange chromatography
Parakeratotic SC from a patient with seborrheic dermatitis was ex-
tracted with a buﬀer containing 20 mM Tris–HCl, pH 8.0, and 1 mM
EDTA. After ﬁltration through a 0.45 lm ﬁlter, the extract was loaded
on a HiTrap QFF anion exchange column with a bed volume of 1 ml
that had been equilibrated with the extraction buﬀer. Protein elution
was achieved with a 0–1 M NaCl gradient. Fractions of 1 ml were
collected and analyzed further.
2.4. Immunochemical analyses
For immunohistochemical analysis, SC squames were scraped oﬀ
from the skin with a scalpel and embedded in cryomatrix (Thermo-
Shandon, Pittsburgh, PA). Immunohistochemistry was performed on
cryosections that were ﬁxed with acetone:ethanol (1:1) using the in-
direct immunoperoxidase staining technique as described [19]. En-
dogenous peroxidase was blocked with methanol/H2O2. The sections
were stained with a mouse monoclonal anti-human caspase-14 anti-
body (Upstate) diluted 1:2000 in Tris-buﬀered saline, pH 7.5, plus 2%
BSA overnight at 4 C. After washing, slides were incubated with
biotinylated sheep anti-mouse IgG (1:10 000) and exposed to strepta-
vidin biotin complex obtained from DAKO (Glostrup, Denmark). 3-
Amino-9-ethylcarbazole was used as chromogen. The slides were
counterstained with hematoxylin. The speciﬁcity of the staining was
conﬁrmed by preabsorption of the ﬁrst step antibody with re-
combinant caspase-14, which blocked the staining. Western blot
analysis was performed according to a previously described protocol
[9].
2.5. Immunodepletion
10 ll of the polyclonal antibody against human procaspase-14, 30 ll
Ultralink Immobilized Protein A Plus beads (Pierce, Rockford, IL)
and 300 ll PBS were incubated on a rotary mixer at 4 C for 2 h.
Subsequently, the beads were washed with PBS and incubated with 300
ll stratum corneum extract (SCE) (1 mg SC/100 ll) at 4 C for 2 h.
After centrifugation, both the supernatant and the material bound to
the beads were analyzed further. For all experiments, control reactions
were performed with pre-immune rabbit serum instead of the anti-
caspase-14 antiserum.
2.6. Caspase activity assay
The catalytic activity of SCEs was determined in an assay system
similar to the one described by Boatright and colleagues [17] for re-
combinant caspases-8 and -9 with modiﬁcations. In brief, 30 ll PBS-
extract from SC was added to microtiter plate wells containing 70 ll
reaction mixture so that the ﬁnal concentrations were 1.3 M sodium
citrate pH 7.0, 5 mM dithiothreitol, and 100 or 200 lM tetrapeptide-p-
nitroaniline (pNA). Then, the plate was incubated at 37 C and the
absorbance at 405 nm was measured. DEVD-pNA, IETD-pNA,
WEHD-pNA, and YVAD-pNA were purchased from Apotech, Vi-
enna, Austria. zVAD-fmk was obtained from Alexis Corp., Vienna,
Austria.3. Results
3.1. Processing of caspase-14 is complete in normal SC but not
in parakeratotic SC
Since SC is the most superﬁcial layer of the epidermis and
contains the subunits of caspase-14 [9], it is an ideal source
for endogenous caspase-14. SC was collected from the heels
of healthy volunteers, from psoriatic lesions and from af-
fected skin of a patient with seborrheic dermatitis. Immu-
nohistochemical analysis of SC squames revealed the
presence of caspase-14 in all samples (Fig. 1A–C). The
staining was inhomogeneous, which may reﬂect either uneven
distribution of caspase-14 throughout SC or a partial loss of
the antigen during the immunohistochemical procedure.
Hematoxylin staining revealed that in contrast to normal
orthokeratotic SC (Fig. 1A), SC from psoriatic skin and
from seborrheic dermatitis skin was parakeratotic, i.e., it
contained nuclei (Fig. 1B, C). Protein extraction with PBS
from SC of normal skin yielded the caspase-14 subunits p17
and p11 but not procaspase-14 as demonstrated by Western
blotting (Fig. 1D, lane 1). In contrast, signiﬁcant amounts of
procaspase-14 together with caspase-14 subunits were present
in parakeratotic SC (Fig. 1D, lanes 2 and 3). Essentially, the
same results were obtained when instead of PBS an extrac-
tion buﬀer containing SDS was used (Fig. 1D, lanes 4–6).
These results indicate that during normal terminal keratino-
cyte diﬀerentiation in healthy skin, the entire pool of pro-
caspase-14 of keratinocytes is converted to caspase-14
subunits, whereas incomplete diﬀerentiation manifesting as
parakeratosis leads only to partial processing of procaspase-
14.
Table 1
Substrate speciﬁcity of endogenous caspase-14
Substrate SCE
(aU)
SCE–C14
(aU)
Activity
depleted (aU)
Depletion
(%)
WEHD 137 7 13 1 124 91
IETD 22 1 2 1 20 91
YVAD 17 0 4 0 13 76
DEVD 5 4 6 4 0 0
SCE was analyzed for cleavage activity against the tetrapeptide sub-
strates, WEHD-pNA, IETD-pNA, YVAD-pNA, and DEVD-pNA, as
described in Section 2. For the determination of the contribution of
caspase-14 to the observed activities, SCE was immunodepleted of
caspase-14 prior to the activity assay (SCE-C14). The catalytic activity
was determined by measuring mOD405 after 6 h incubation with each
substrate (aU, arbitrary units). The activity depleted by removal of
caspase-14 was calculated as absolute value and as percentage of the
activity of untreated SCE.
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To test for catalytic activity of epidermal caspase-14, we
extracted SC of normal human skin with PBS and incubated
the extract with the synthetic tetrapeptide substrate WEHD-
pNA under various assay conditions. In standard caspase ac-
tivity buﬀers, minimal to undetectable catalytic activity was
observed, indicating that conventional caspases with high ac-
tivity towards WEHD were not present in signiﬁcant amounts
in the extract (not shown). Western blot analysis for caspase-1,
i.e., the caspase with the highest aﬃnity for WEHD [20],
conﬁrmed that it was absent from the extract (not shown).
However, when a high concentration of sodium citrate was
used, strong caspase activity was detected (Fig. 2A). The re-
action was completely blocked by addition of the pan-caspase
inhibitor zVAD-fmk (10 lM), conﬁrming the speciﬁcity of a
caspase-mediated cleavage (Fig. 2A). To test whether this ac-
tivity was attributable to caspase-14, we removed caspase-14
from the extract by immunoprecipitation and analyzed the
residual WEHDase activity. Immunodepletion of caspase-14
virtually abolished WEHDase activity (Fig. 2A), whereas a
control reaction performed with immunobeads coated with
pre-immune serum instead of anti-caspase-14 serum did not
decrease the activity (Fig. 2A). Western blot analysis showed
that the untreated SCE contained the same amount of the
caspase-14 p17 subunit as the supernatant of the control de-Fig. 2. Caspase-14 extracted from SC is catalytically active. SCE was
prepared from plantar skin by incubation of SC squames with PBS.
Part of SCE was subjected to immunoprecipitation with anti-caspase-
14 serum (casp-14 depletion) or with preimmune control serum (con-
trol depletion). Untreated SCE, immunodepleted SCE and SCE
preincubated with the pan-caspase inhibitor zVAD-fmk (10 lM) were
analyzed for caspase activity using the colorimetric tetrapeptide sub-
strate WEHD-pNA under kosmotropic conditions (A). Cleavage of
the substrate was determined by milli-units of optical density at 405 nm
(mOD405). The eﬃciency of immunodepletion of caspase-14 was
evaluated by Western blot analysis with a monoclonal antibody that
reacts with procaspase-14 and with the large subunit of caspase-14
(p17) (B). Untreated SCE as well as the supernatants (SN) of the im-
munobeads and the proteins bound to the immunobeads (IP) were
analyzed. The position of the p17 subunit of caspase-14 is indicated by
an arrow. Procaspase-14 was not present.pletion, whereas the supernatant of the caspase-14 immuno-
depletion contained only minimal amounts thereof (Fig. 2B).
Accordingly, caspase-14 protein was found on beads coated
with anti-caspase-14 serum but not on control beads (Fig. 2B).
The proteins that bound to beads coated with anti-caspase-14
antibody displayed signiﬁcant WEHDase activity, whereas
proteins adhering to the control beads were catalytically in-
active (not shown). In addition to WEHD-pNA, the extract
was also active against IETD-pNA and YVAD-pNA, whereas
only minimal activity against DEVD-pNA was observed (Ta-
ble 1). IETDase and YVADase could be removed by caspase-
14 depletion, whereas the weak DEVDase activity remained
unchanged. These results show for the ﬁrst time that endoge-
nous caspase-14 present in SC is catalytically active. Further-
more, the fact that most of the caspase activity could be
removed by immunodepletion of caspase-14 suggests that
caspase-14 is the predominant active caspase in normal SC.
3.3. In parakeratotic SC, caspase-14 activity is associated with
processed caspase-14 subunits but not with procaspase-14
Next, we investigated the composition and activity of cas-
pase-14 complexes in tissue samples that contain both pro-
cessed and unprocessed caspase-14. An extract from
parakeratotic SC was separated by anion exchange chroma-
tography and the fractions were analyzed for the presence of
caspase-14 protein species and WEHDase activity. As shown
in Fig. 3, procaspase-14 was eluted at lower salt concentrations
than the subunits of caspase-14. Signiﬁcant signals of the p28
band (procaspase-14) were detected in fractions 29–35,
whereas the p17 band (large subunit) was present in fractions
31 through 37. Despite the big diﬀerence in isoelectric points
(pI) of the large (pI 4.78) and the small subunit (pI 9.13) of
caspase-14, they were eluted in the same fractions of anion
exchange chromatography. This indicated that the subunits
are present as a complex in SCEs. WEHDase activity was
analyzed under kosmotropic conditions and correlated strictly
with the intensity of the caspase-14 p17 band (Fig. 3), whereas
it did not correlate with the amount of procaspase-14. This
activity proﬁle was apparently not inﬂuenced by other casp-
ases, since there was no WEHDase activity in the fractions
containing caspase-14 when standard caspase buﬀers were
used (not shown). Furthermore, caspase-1 was not detected by
Western blotting (not shown). Our data therefore suggest that
the catalytic activity of processed caspase-14 is much higher
than that of procaspase-14.
Fig. 3. Caspase-14 activity is associated with processed caspase-14
subunits but not with procaspase-14. Parakeratotic SC was extracted
with Tris-EDTA buﬀer and fractionated by anion exchange chroma-
tography as described in ‘‘Materials and Methods’’. The concentration
of sodium chloride corresponding to the eluted fractions is shown at
the top. Aliquots were subjected to SDS-PAGE and immunoblotted
with a polyclonal anti-caspase-14 antibody that reacts with procas-
pase-14 and with the subunits, p17 and p11 (A). WEHDase activity of
the fractions was measured as described in Fig. 2A (B). Arbitrary ac-
tivity units shown here are deﬁned as mOD405 after 1 hour incubation
with WEHD-pNA under kosmotropic conditions.
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The present investigations were based on our observation
that endogenous caspase-14 can be extracted from SC by in-
cubation with detergent-free buﬀer. This suggests that caspase-
14 subunits either are released from the corniﬁed keratinocyte
remnants (corneocytes) during the extraction process or are
present in the intercorneocyte space. Previously, it was shown
that procaspase-14 remains uncleaved as long as SC formation
is not induced [9,11]. However, it is presently unclear whether
procaspase-14 is processed in diﬀerentiating keratinocytes
prior to the transition into the SC or only thereafter, i.e.,
within SC. Our ﬁnding that all caspase-14 is processed in or-
thokeratotic SC whereas a fraction of procaspase-14 remains
unprocessed in SC containing parakeratotic areas suggests that
incomplete caspase-14 activation is associated with diseased
skin phenotypes. Intriguingly, a recent study shows that a
Vitamin D3 analog that is used for treatment of psoriasis is
able to enhance caspase-14 processing in an in vitro skin model
[21]. Whether the potential eﬀect of psoriasis therapies on
caspase-14 processing correlates with treatment eﬃciency re-
mains to be determined.
The observation of catalytic activity in SCEs containing only
cleaved caspase-14 and the correlation of caspase activity with
the amount of caspase-14 subunits but not with the amount of
procaspase-14 in chromatography fractions indicate that the
subunits of caspase-14 are catalytically active, whereas the
proenzyme has weak or no activity. In addition, our data
strongly argue against the hypothesis that the physiological
form of activated caspase-14 is a complex of procaspase-14and the subunits, as proposed by Chien and colleagues [15].
Whereas the proenzyme and the large subunit of caspase-14
could be separated partially by anion exchange chromatogra-
phy, the large and the small subunit coeluted under the same
conditions. This indicates that the subunits are present in the
form of a complex in SCEs.
Enzymatic activity of SC-derived caspase-14 was only ob-
served at a high concentration of citrate. Since equal con-
centrations of NaCl did not induce activity (not shown), this
eﬀect does not seem to be mediated by high salt concentra-
tions in general but rather by the kosmotropic properties of
citrate. Kosmotropes, a term coined by Washabaugh and
Collins for ‘‘water structure making’’ ions [22], bind water
molecules in aqueous solutions more eﬀectively than proteins,
thereby establishing conditions that favor interactions be-
tween protein domains over interactions between protein and
water [22]. Conditions with comparable impact on enzyme
activity may be present in SC. The water content of SC is
much lower than in other skin compartments and decreases
strongly from the inner to the outer layers where it reaches
15 to 25% [23,24]. Furthermore, various ions including cit-
rate are present at elevated concentrations in SC as com-
pared to other tissues [25]. The conditions in aqueous
microdomains of SC [26], where hydrolytic enzyme reactions
are likely to take place, are largely unknown at present.
Further studies will be necessary to determine which partic-
ular parameters or cofactors present in skin facilitate cas-
pase-14 activity in vivo.
Our data regarding requirement for kosmotropic reaction
conditions and substrate preference for WEHD are in accor-
dance with results recently reported for recombinant caspase-
14 [16]. Therefore, recombinant caspase-14 appears to be a
valid model for the investigation of caspase-14 activity, even
when it is not processed by its endogenous activator, which is
currently unknown, but by granzyme B at an unphysiological
site between the subunits [16].
In conclusion, the present study demonstrates that caspase-
14 is present in its active form in SC and that it is the major, if
not only, caspase active at this site. As to the biological
function of this enzyme, our data indicate that the search for
potential substrates of caspase-14 should be focused on pro-
teins of the outermost skin layers. Our demonstration that
large quantities of active caspase-14 can be obtained easily by
non-invasive procedures from SC provides a good starting
point for further studies.
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